Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Cited by (562)

Items 301–400 of 562

1. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment
   Tong Shu, Yi Li, Xiaowei Wu, Bin Li, Zhihua Liu · 2017 · Cancer Letters
2. Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma
   Stephan Arni, Thi Hong Nhung Le, Rik de Wijn, Refugio Garcı́a-Villegas, Martjin Dankers, Walter Weder, Sven Hillinger · 2017 · Oncotarget
3. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment
   Xiaoping Song, Wei Tang, Hui Peng, Xin Qi, Jing Li · 2021 · Investigational New Drugs
4. AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
   Salony, Xavier Solé, Cleidson Padua Alves, Ipsita Dey‐Guha, Laila Ritsma, Myriam Boukhali, Ju H. Lee, Joeeta Chowdhury, Kenneth N. Ross, Wilhelm Haas et al. · 2015 · Molecular Cancer Therapeutics
5. Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma
   Yojiro Makino, Jeong‐Hwan Yoon, Eunjin Bae, Mitsuyasu Kato, Keiji Miyazawa, Tatsuo Ohira, Norihiko Ikeda, Masahiko Kuroda, Mizuko Mamura · 2017 · Biochemical and Biophysical Research Communications
6. Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
   Ho-June Lee, Yi Cao, Victoria C. Pham, Elizabeth R. Blackwood, CATHERINE A. WILSON, Marie Evangelista, Christiaan N. Klijn, David Stokoe, Jeff Settleman · 2017 · Molecular Cancer Therapeutics
7. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
   Anna Orlova, Bettina Wingelhofer, Heidi Anne Neubauer, Barbara Maurer, Angelika Berger‐Becvar, György Miklós Keserű, Patrick Thomas Gunning, Peter Valent, Richard Moriggl · 2017 · Expert Opinion on Therapeutic Targets
8. Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo
   Zhe Liu, Xianmin Ge, Yuchen Gu, Yingying Huang, Hao Liu, Meiling Yu, Yamin Liu · 2019 · Biomedicine & Pharmacotherapy
9. Loss of LGR5 through Therapy-induced Downregulation or Gene Ablation Is Associated with Resistance and Enhanced MET-STAT3 Signaling in Colorectal Cancer Cells
   Tressie A. Posey, Joan Jacob, Ashlyn N. Parkhurst, Shraddha Subramanian, Liezl E. Francisco, Zhengdong Liang, Kendra S. Carmon · 2023 · Molecular Cancer Therapeutics
10. pSTAT3 activation of Foxl2 initiates the female pathway underlying temperature-dependent sex determination
    Pengfei Wu, Xifeng Wang, Chutian Ge, Lin Jin, Zihan Ding, Fang Liu, Ju Zhang, Fei Gao, Wei‐Guo Du · 2024 · Proceedings of the National Academy of Sciences
11. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in theJAK2gene in non-small cell lung cancer
    Tao Shen, Zhengming Chen, Zhizhuang Joe Zhao, Jie Wu · 2017 · Oncotarget
12. Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation
    Jianchao Zheng, Biao Duan, Shixiu Sun, Jie Cui, Jun Du, Yujie Zhang · 2017 · Frontiers in Pharmacology
13. Tyrosine kinase inhibitor‐induced IL‐6/STAT3 activation decreases sensitivity of EGFR‐mutant non‐small cell lung cancer to icotinib
    Jinyao Wang, Yizhe Wang, Chunlei Zheng, Kezuo Hou, Tieqiong Zhang, Xiujuan Qu, Yunpeng Liu, Jian Kang, Xuejun Hu, Xiaofang Che · 2018 · Cell Biology International
14. A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling
    Xiaomin Ding, Danqing Lu, Jianbo Fan · 2021 · Bioscience Biotechnology and Biochemistry
15. Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth
    Xiaomeng Xie, Xiangyu Wang, Xiaodan Shi, Yuanyuan Zhang, Kyle Vaughn Laster, Kangdong Liu, Zigang Dong, Dong Joon Kim · 2021 · Journal of Cellular and Molecular Medicine
16. Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3
    Xin Qi, Meng Li, Xiaomin Zhang, Xiu-fen Dai, Jian Tao Cui, Dehai Li, Qianqun Gu, Zhihua Lv, Jing Li · 2020 · Molecules
17. Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway
    Cong Hou, Lijun Lu, Zhanye Liu, Yingjie Lian, Jianguang Xiao · 2021 · FEBS Open Bio
18. STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy
    Wei‐Jing Gong, Liyun Ma, Lei Hu, Yongning Lv, Hong Bing Huang, Jiaqiang Xu, Dandan Huang, Ruijie Liu, Yong Kwon Han, Yu Zhang et al. · 2019 · International Journal of Clinical Oncology
19. Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib
    Xin Lyu, Lizhong Zeng, Jie Shi, Zongjuan Ming, Wei Xiao Li, Boxuan Liu, Yang Chen, Bo Yuan, Ruiying Sun, Jingyan Yuan et al. · 2022 · Journal of Experimental & Clinical Cancer Research
20. High throughput and automatic colony formation assay based on impedance measurement technique
    Kin Fong Lei, Chich-Hao Kao, Ngan‐Ming Tsang · 2017 · Analytical and Bioanalytical Chemistry
21. Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
    Jamie A. Saxon, Taylor P. Sherrill, Vasiliy V. Polosukhin, Jiqing Sai, Rinat Zaynagetdinov, Allyson G. McLoed, Peter M. Gulleman, Whitney Jo Barham, Dong‐Sheng Cheng, Raphael P. Hunt et al. · 2016 · OncoImmunology
22. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling
    Xiaowen Zhou, Bojia Liu, Qing Xiu Ning, Zhi Xia, Rongling Zhong, Li Zhang, Lei Wu · 2020 · Oncology Reports
23. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
    Seul‐Ki Cheon, Hwang‐Phill Kim, Ye‐Lim Park, Jee‐Eun Jang, Yoojoo Lim, Sang‐Hyun Song, Sae‐Won Han, Tae‐You Kim · 2018 · Molecular Oncology
24. Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies
    Haifeng Li, Wenlong Xu, Wenqi Cheng, Guanxiao Yu, Dongmei Tang · 2025 · Frontiers in Pharmacology
25. STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1
    M. E. Picco, María Victoria Castro, María Josefina Quezada, G. Barbero, María Belén Villanueva, Natalia B. Fernández, Hyungsoo Kim, P. Lopez-Bergami · 2019 · Cell & Bioscience
26. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
    Sukhmani Kaur Padda, Karen L. Reckamp, Marianna Koczywas, Joel W. Neal, Jun Kawashima, Shengchun Kong, Daniel B. Huang, Mark Marion Kowalski, Heather A. Wakelee · 2021 · Cancer Chemotherapy and Pharmacology
27. Conquering oncogenic KRAS and its bypass mechanisms
    Pingping Hou, Yanru Wang · 2022 · Theranostics
28. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs
    Kelsey L. Polak, Ilaria Tamagno, Neetha Parameswaran, Jacob M. Smigiel, Ernest Ricky Chan, Xueer Yuan, Brenda L. Rios, Mark W. Jackson · 2023 · Molecular Cancer Research
29. The importance of integrated therapies on cancer: Silibinin, an old and new molecule
    Elisa Roca, Giuseppe A. Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra Cucinella, Giorgio Madonia, Licia Martinelli, Maria Eugenia Damiani, Ilaria Zampieri, Antonio Santo · 2024 · Oncotarget
30. STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback
    Ruolan Zeng, Youhong Tang, Hui Zhou, Yiping Liu, Junhui Huang, Li Li, Wei Liu, Yuhua Feng, Yangying Zhou, Taili Chen et al. · 2017 · Biochemical and Biophysical Research Communications
31. High dose acetaminophen inhibits STAT3 and has free radical independent anti-cancer stem cell activity
    Pavani Pingali, Y. Jeffrey Wu, Rio S. Boothello, Chetna Sharon, Howard Y. Li, Srinivas Sistla, Nehru Viji Sankaranarayanan, Umesh R. Desai, Anh Tuan Le, Robert Charles Doebele et al. · 2021 · Neoplasia
32. Targeting the gp130/STAT3 Axis Attenuates Tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma Cells
    Lakshana Sreenivasan, Ling Vicky Li, Pascal Leclair, Chinten James Lim · 2022 · Cells
33. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
    Martin Sattler, Isa Mambetsariev, Jeremy Fricke, Tingting Tan, Sariah Liu, Nagarajan Vaidehi, Evan P. Pisick, Tamara Mirzapoiazova, Adam G. Rock, Amartej Merla et al. · 2023 · Journal of Clinical Medicine
34. Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy
    Antoine Buetti‐Dinh, Thomas O’Hare, Ran Friedman · 2016 · PLoS ONE
35. Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer
    Simon Vyse, Annie Howitt, Paul H. Huang · 2017 · Journal of Molecular Biology
36. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma
    Li-Hua Jiang, Ying-Li Hao, Jingwei Zhu · 2018 · Clinics and Research in Hepatology and Gastroenterology
37. Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
    Wei Xiong Wen, Ernest Soyoung Han, Thanh Hue Dellinger, Leander X. Lu, Jun Wu, Richard Jove, John Hosei Yim · 2020 · Cancers
38. Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling
    Ladislav Sivák, Vladimír Šubr, Jiřina Kovářová, Barbora Dvořáková, Milada Šírová, Blanka Řı́hová, Eva Randárová, Michal Kraus, Jakub Tomala, Martin Studenovský et al. · 2021 · Journal of Controlled Release
39. Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib
    Viktoria von Manstein, Bernd Groner · 2016 · MedChemComm
40. The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis
    Guiqin Xu, Zhaojuan Yang, Yizong Ding, Yun Liu, Li Zhang, Boshi Wang, Ming Tang, Tiantian Jing, Kun Jiao, Xiaoli Xu et al. · 2021 · Oncogene
41. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
    Nobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, Ai Takemoto, Tomoko Oh‐hara, Ken Uchibori, Sophia Subat-Motoshi, Hironori Ninomiya, Kengo Takeuchi, Makoto Nishio et al. · 2023 · JCI Insight
42. YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells
    Ryousei Sasaki, Shigeki Ito, Maki Asahi, Yoji Ishida · 2015 · Leukemia Research
43. L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway
    Encheng Bai, Lehe Yang, Youqun Xiang, Wanle Hu, Caleb Li, Jiayuh Lin, Xuanxuan Dai, Guang Liang, Rong Jin, Chengguang Zhao · 2018 · Cancer Management and Research
44. Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
    Esra A. Akbay, James Kim · 2018 · Translational Lung Cancer Research
45. If You Cannot Win Them, Join Them: Understanding New Ways to Target STAT3 by Small Molecules
    Francesc Sabanés Zariquiey, João V. da Souza, Roger Estrada‐Tejedor, Agnieszka K. Bronowska · 2019 · ACS Omega
46. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)
    Qiuyao Huang, Yan Zhong, Bingbing Li, Shumin Ouyang, Linhong Deng, Jianshan Mo, Shuo Shi, Nan Lv, Ruibo Wu, Peiqing Liu et al. · 2021 · European Journal of Medicinal Chemistry
47. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells
    Qian Wang, Bing Lu, Yi Zhang, Jing Yu, Jie Fang Guo, Qianchi Zhou, Hong Lv, Yifeng Sun · 2021 · Human Cell
48. Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
    Ke Gong, Gao Guo, Nicole A. Beckley, Xiaoyao Yang, Yue Zhang, David E. Gerber, John Dorrance Minna, Sandeep Burma, Dawen Zhao, Esra A. Akbay et al. · 2021 · Nature Communications
49. STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
    Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Azusa Tanimoto, Akihiro Nishiyama, Naohisa Ogo, Hiroyuki Takahashi, Akira Asai, Satoshi Watanabe et al. · 2022 · npj Precision Oncology
50. APC/C CDH1 ubiquitinates STAT3 in mitosis
    Debanjan Bhattacharjee, Sreeram Kaveti, Nishant Jain · 2022 · The International Journal of Biochemistry & Cell Biology
51. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
    Deepak Vangala, Swetlana Ladigan, Sven Thorsten Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein‐Scory, Laura Godfrey, Martina K. Zowada et al. · 2021 · Genome Medicine
52. RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
    Ahlem Jebali, Maxime Battistella, Célèste Lebbé, Nicolas Dumaz · 2021 · Biomedicines
53. ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
    Chiara Pozzato, Gonçalo Outeiro-Pinho, Mirco Galiè, Giorgio Ramadori, Georgia Konstantinidou · 2024 · EMBO Molecular Medicine
54. Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation
    Beiyuan Zhang, Chao Qin, Xue Wang, Chuanhong Shen, Shuo Li, Taiyu Liu, Wenqing Li, Zhaojie Chen, Ya‐Wen Wang, Lisha Liu et al. · 2025 · Journal of Controlled Release
55. The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
    Torunn Wendel, Yan Zhen, Zenhe Suo, Skjalg Bruheim, Antoni Więdłocha · 2015 · Experimental Cell Research
56. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
    Alessia Spagnuolo, Paolo Maione, Cesare Gridelli · 2022 · Translational Lung Cancer Research
57. Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review)
    Wen-Kai Li, Yunjing Zhuang, Songjun Shao, Pankaj Trivedi, Biying Zheng, Guoliang Huang, Zhiwei He, Xiangning Zhang · 2024 · Molecular Medicine Reports
58. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer
    Nobuaki Ochi, Hideko Isozaki, Masami Takeyama, Jack W. Singer, Hiromichi Yamane, Yoshihiro Honda, Katsuyuki Kiura, Nagio Takigawa · 2016 · Experimental Cell Research
59. Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
    Yan Zhou Tran, Rezan Minozada, Xiaofang Cao, Henrik J. Johansson, Rui Mamede Branca, Brinton A. Seashore-Ludlow, Lukas M. Orre · 2020 · Molecular & Cellular Proteomics
60. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
    Joaquim Bosch‐Barrera, Sara Verdura, José Carlos Ruffinelli, Enric Carcereny, Èlia Sais, Elisabet Cuyàs, Ramón Palmero, Eugeni López‐Bonet, A. Hernández, Glòria Oliveras et al. · 2021 · Cancers
61. Pharmacological management of relapsed/refractory NSCLC with chemical drugs
    Niki Karachaliou, Aaron E. Sosa, Feliciano Barrón, María González Cao, Mariacarmela Santarpía, Rafael Rosell · 2017 · Expert Opinion on Pharmacotherapy
62. Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro
    Qiuyue Liao, Xue Feng, Xi Li, Ge Chen, Jing Chen, Bin Yang, Kezhen Li, Jihui Ai · 2020 · Oncology Reports
63. Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells
    Rawan Hallal, Rawan Nehme, Marie Brachet‐Botineau, Ali Nehme, Hassan Dakik, Margaux Deynoux, Persio Dello Sbarba, Yves Le Vern, Kazem Zibara, Fabrice Gouilleux et al. · 2020 · Journal of Cellular and Molecular Medicine
64. Signal transducer and activator of transcription 3 mediates apoptosis inhibition through reducing mitochondrial ROS and activating Bcl‐2 in gemcitabine‐resistant lung cancer A549 cells
    Jiansheng Liu, Chun‐An Yeh, I‐Chieh Huang, Guan‐Yu Huang, Chih‐Hao Chiu, B. Mahalakshmi, Su‐Ying Wen, Chih‐Yang Huang, Wei‐Wen Kuo · 2020 · Journal of Cellular Physiology
65. Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
    Shusil K. Pandit, Giada Sandrini, Jessica Merulla, Valentina Nobili, Xin Wang, Alessia Zangari, Andrea Rinaldi, Dheeraj A. Shinde, Giuseppina Maria Carbone, Carlo Vittorio Catapano · 2021 · Cancers
66. Epigenetic adaptations in drug-tolerant tumor cells
    Nilanjana Mani, Ankita Daiya, Rajdeep Chowdhury, Sudeshna Mukherjee, Shibasish Chowdhury · 2023 · Advances in cancer research
67. Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
    Jina Choi, Nayoung Kim, Ryoung Hee Nam, Jin Won Kim, Chin‐Hee Song, Hee Young Na, Gyeong Hoon Kang · 2023 · PLoS ONE
68. Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway
    Xian-Ping Dai, Feng Geng, Jiale Dai, Mengshun Li, Ming Liu · 2018 · Medical Science Monitor
69. A new insight into the reversal of multidrug resistance in cancer by nanodrugs
    Huangyong Jiang, Dongbo Guo, Dong Chen, Yan Fen Wu, Xin Jin, Xinyuan Zhu · 2019 · Biomaterials Science
70. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
    Laura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, Jennifer Dworacek, Aniello Federico, Marlene Vierthaler, Daniel Novak, Ihor Arkhypov, Thomas Hielscher, Viktor Umansky et al. · 2020 · Cancers
71. Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer
    Jennifer Rubin Grandis, Katherine A. Skorupski, Ning Cheng, Zhibin Cui, Hua Li, Liam C. Woerner, Jovanka Gencel‐Augusto, Yan Zeng, Jamie V. Shiah, Neil E. Bhola et al. · 2025 · Cancer Cell
72. Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity
    Chia‐Hung Chen, Tzu‐Han Weng, Cheng‐Hsun Chuang, Kai‐Yao Huang, Sih-Cheng Huang, Pin-Rong Chen, Hsiao-Hsuan Huang, Ling-Ya Huang, Pei-Chun Shen, Po-Ya Chuang et al. · 2022 · Nanomedicine Nanotechnology Biology and Medicine
73. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Niki Karachaliou, Jordi Codony‐Servat, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Martyna Filipska, Carlos Pedraz‐Valdunciel, Imane CHAIB-OUKADOUR, Jordi Bertrán-Alamillo, Andrés Felipe Cardona, Miguel Ángel Molina‐Vila et al. · 2019 · Expert Review of Respiratory Medicine
74. Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition
    Xudong Wang, Chiho Kim, Yajie Zhang, Smita Rindhe, Melanie H. Cobb, Yonghao Yu · 2021 · Journal of Proteome Research
75. Ningalins, Pyrrole‐Bearing Metabolites Isolated from Didemnum spp. Synthesis and MDR‐Reversion Activity in Cancer Therapy
    Luis A. Segura‐Quezada, Edson D. Hernández‐Velázquez, Alma Rosa Corrales Escobosa, Claudia de León‐Solís, Cesar Rogelio Solorio‐Alvarado · 2023 · Chemistry & Biodiversity
76. Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis
    He Shen, Nuo Yang, Alexander M. Truskinovsky, Yanmin Chen, Ashley L. Mussell, Norma J. Nowak, Lester Kobzik, Costa G. Frangou, Jianmin Zhang · 2018 · Molecular Cancer Research
77. PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer
    Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Jordi Berenguer, Manuel Fernández-Bruno, Martyna Filipska, Carlos Pedraz‐Valdunciel, Carles Codony, Jordi Codony‐Servat, Rafael Rosell · 2019 · Journal of Cancer Metastasis and Treatment
78. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
    Oh, Hwanhee, Hwang, Inah, Jang, Ja-Young, Wu, Lingxiang, Cao, Dongqing, Yao, Jun, Ying, Haoqiang, Li, Jian Yi, Yao, Yu, Hu, Baoli et al. · 2021 · Cancer Research
79. Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription
    Alessandro Carugo, Giulio Francesco Draetta · 2018 · Cancer Discovery
80. An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1
    Fareesa Aftab, Alice Rodriguez-Fuguet, Luis Silva, Ikei S. Kobayashi, Jiao Sun, Katerina A. Politi, Elena Levantini, Wei Zhang, Susumu S. Kobayashi, Wen Cai Zhang · 2023 · British Journal of Cancer
81. Immune cells in residual disease and recurrence
    Yasemin Ceyhan, Nina Marie G. Garcia, James V. Alvarez · 2023 · Trends in cancer
82. Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
    H. Rudolf de Boer, Martin Pool, Esméé Joosten, Marieke Everts, Douwe Freerk Samplonius, Wijnand Helfrich, Harry J.M. Groen, Suzanne van Cooten, Fabrizia Fusetti, Rudolf S.N. Fehrmann et al. · 2018 · Oncogene
83. H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA
    Fengli Li, Jing Wang, Ning Wu, Hua Zhang, Zheng Li, Ning Wei · 2019 · Biochemical and Biophysical Research Communications
84. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer
    Junjun Chen, Jie Dai, Zhiming Kang, Ting Yang, Qi Zhao, Jinxiu Zheng, Xinxin Zhang, Jisheng Zhang, Jun Xu, Gongqin Sun et al. · 2020 · Experimental Cell Research
85. YAP confers resistance to vandetanib in medullary thyroid cancer
    Huan Wang, Jian Tang, Zhiwei Su · 2020 · Biochemistry and Cell Biology
86. Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy
    Xiaoqiang Sun, Jiajun Zhang, Qi Zhao, Xing Chen, Wenbo Zhu, Guangmei Yan, Tianshou Zhou · 2016 · BMC Systems Biology
87. Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer
    Sridevi Challa, Kazim M. Husain, Richard Kim, Domenico Coppola, Surinder K. Batra, Jin Quan Cheng, Mokenge Peter Malafa · 2020 · Translational Oncology
88. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs
    Jamie L. Grit, Lauren E. McGee, Elizabeth A. Tovar, Curt J. Essenburg, Emily Wolfrum, Ian Beddows, Kaitlin L. Williams, Rachael T. C. Sheridan, J.L. Schipper, Marie Adams et al. · 2024 · Oncogene
89. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
    P. Narayanan, Tsz‐Kwong Man, Robert B. Gerbing, Rhonda E. Ries, Alexandra McLean Stevens, Y.-C. Wang, Xin Long, Alan S. Gamis, Todd M. Cooper, Soheil Meshinchi et al. · 2021 · Clinical & Translational Oncology
90. A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
    Sunanda Singh, Genoveva Murillo, Justin M. Richner, Samara P. Singh, Erica S. Berleth, Vijay Kumar, Rajendra G. Mehta, Vijay Ramiya, Ashutosh S. Parihar · 2022 · International Journal of Molecular Sciences
91. The Ethanolic Extract of Trichosanthes Kirilowii Root Exerts anti-Cancer Effects in Human Non-Small Cell Lung Cancer Cells Resistant to EGFR TKI
    Hyun-Ji Park, Shin‐Hyung Park · 2022 · Nutrition and Cancer
92. Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer
    Kaixuan Shi, Haijiao Lu, Zhenfeng Zhang, Yujie Fu, Jie Wu, Shichao Zhou, Pengfei Ma, Kaiyan Ye, Shengzhe Zhang, Hailei Shi et al. · 2022 · Cell Death and Differentiation
93. The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
    Tinghao Yan, Xinchen Tian, Fen Liu, Qingbin Liu, Qing Sheng, Jianlin Wu, Shulong Jiang · 2022 · Frontiers in Oncology
94. Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies
    Valerio Gelfo, Francesca Pontis, Martina Mazzeschi, M. Sgarzi, M. Mazzarini, R. Solmi, G. D'Uva, M. Lauriola · 2019 · Journal of Clinical Medicine
95. Partners in crime: POPX2 phosphatase and its interacting proteins in cancer
    Pu Rum Kim, Songjing Zhang, Muhammad Bakhait Bin Rahmat, Cheng-Gee Koh · 2020 · Cell Death and Disease
96. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma
    Jiaxin Cao, Kangmei Zeng, Qun Chen, Ting Yang, Feiteng Lu, Chaozhuo Lin, Jianhua Zhan, Wenjuan Ma, Ting Zhou, Yan Huang et al. · 2024 · Cell Death and Disease
97. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis
    Juan Zhang, Xuefeng Gao, Mingming Wei, Yonghui Li, Guang Yang, Cheng Yang, Li Yu · 2021 · Clinical Science
98. Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
    Sonia M Novo, Stephen R. Wedge, Lesley A. Stark · 2017 · Scientific Reports
99. Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells
    Nimmi A. Thomas, Rita G. Abraham, Brixhilda Dedi, Nancy A. Krucher · 2018 · International Journal of Oncology
100. Aminocyanopyridines as anti‐lung cancer agents by inhibiting the STAT3 pathway
     Lingyuan Xu, Sensen Qiu, Lehe Yang, Haitang Xu, Xu Liu, Shiqian Fan, Ri Cui, Weitao Fu, Chengguang Zhao, Liqun Shen et al. · 2019 · Molecular Carcinogenesis